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Introduction
Lung cancer is the most common cause of cancer
death in Hong Kong and accounted for 29% of all
cancer deaths in 1995.1 Of the four major histological
subtypes of lung cancer, small-cell carcinoma is the
most responsive to chemotherapy and radiotherapy. In
contrast, squamous cell carcinoma, adenocarcinoma,
and large cell carcinoma are relatively resistant to
chemotherapy and radiotherapy. These three disease
types are collectively referred to as non–small-cell lung
cancer (NSCLC) and account for approximately 80%
of all primary lung cancers.2
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Objective. To review the role of chemotherapy in advanced non–small-cell lung cancer, focusing on cisplatin-
based regimens and two new drugs: paclitaxel and gemcitabine.
Data sources. Medline search of the relevant English literature.
Study selection. Open and randomised comparative (phases II and III) studies, and meta-analyses of cytotoxic
drugs/regimens used to treat advanced non–small-cell lung cancer.
Data extraction. The following factors were studied and compared: symptomatic response rates; tumour re-
sponse rates; median survival time and 1-year survival rates; and side effects of cisplatin-, paclitaxel-, and
gemcitabine-based regimens.
Data synthesis. Using cisplatin-based chemotherapy achieves significant relief of disease-related symptoms of
advanced non–small-cell lung cancer and a slight improvement in the median survival time (by approximately
1.5 months). New cytotoxic drugs that are effective and have good safety profiles include paclitaxel and
gemcitabine. When used as single agents, these two drugs give response rates of approximately 25%. When
used with cisplatin/carboplatin, response rates increase to 45% to 62% and 1-year survival rates increase to
40% to 60%.
Conclusion. Paclitaxel, gemcitabine, and other drugs such as decetaxel and vinorelbine are promising new
chemotherapeutic agents in the treatment of advanced non–small-cell lung cancer. These drugs can palliate
disease symtoms and improve the median survival time. The optimal dose and treatment schedules, however,
are yet to be defined.
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The treatment of NSCLC depends on the stage of
the disease, as denoted by the tumour-node-metastasis
(TNM) staging system,3 which is used internationally.
Stage IIIB disease is locally advanced disease and
stage IV disease indicates that metastasis has occurred;
these two stages account for approximately 60% of all
cases of lung cancer on presentation.2 Stage IIIB and
IV diseases are advanced diseases that are incurable.
The primary goals of therapy are to palliate symptoms
and, if possible, to prolong survival. Traditionally,
treatment has been only symptomatic and supportive
by giving palliative radiotherapy, pleurodesis for
pleural effusion, or analgesics for pain.
The use of chemotherapeutic agents
In the late 1970s and 1980s, commonly used drugs to
treat NSCLC included cyclophosphamide, mitomycin,
methotrexate, adriamycin, etoposide, fluorouracil,
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vincristine, vinblastine, bleomycin, nitrosoureas, and
cisplatin. Subsequent reviews showed that, of the
conventional cytotoxic drugs, only the following five
gave an objective response rate of 12% or more in
patients with advanced NSCLC when used as single
agents: mitomycin (22%), cisplatin (21%), ifosfamide
(20%), vinblastine (18%), and vindesine (12%).4
Typical combination chemotherapy in the late 1980s
and early 1990s included cisplatin-based regimens
such as cisplatin in various combinations with etopo-
side, adriamycin/epirubicin, vindesine/vinblastine,
and mitomycin and cylophosphamide/ifosfamide.5-7
Does chemotherapy palliate symptoms of
advanced non–small-cell lung cancer?
One of the aims of chemotherapy for advanced NSCLC
is to alleviate disease symptoms, and many clinicians
are concerned that the toxic chemotherapeutic agents
may adversely affect patients’ quality of life and
performance status. This is certainly true for older
agents, particularly alkylating agents, but not the
newer cisplatin-based regimens. A few studies have
addressed the effect of chemotherapy on disease-
related symptoms, such as cough, pain, haemoptysis,
and breathlessness (Table 1).8-11 The studies show that
giving cisplatin-based chemotherapy could alleviate
symptoms in 45% to 92% of patients with NSCLC.8-11
Even modest doses of mitomycin, vinblastine, and
cisplatin combination therapy were able to cause
complete or substantial symptomatic relief in 69%
of patients; only one course of chemotherapy was
needed by 61% of patients and two courses by 96%
(patient response rate, 20% to 30% [n=120]).11
Although previous studies show that modern
chemotherapy can achieve the first goal of therapy
in metastatic lung cancer—namely, the palliation of
symptoms—many of the studies involved relatively
small numbers of patients; thus, the evidence is not
conclusive. Nevertheless, the availability of new,
powerful anti-emetics12,13 and haemopoietic growth
factors14 can help decrease the toxicities and mor-
bidities associated with chemotherapy. Haemopoietic
colony-stimulating factors, for example, have been
used to treat febrile neutropenia induced by a prior
chemotherapy cycle; the treatment avoids infectious
complications and maintains the dose-intensity of
the chemotherapeutic drugs in subsequent treatment
cycles, when chemotherapy dose-reduction is not
appropriate.14
Elaborate test methods to measure the quality of
life in patients with lung cancer are now available
(eg the Lung Cancer Symptoms Scale, the  Quality of
Life Questionnaire of the European Organisation for
the Research and Treatment of Cancer, the Rotterdam
Symptom Checklist, the Functional Living Index-
Cancer, and the Daily Diary Card).15,16 The quality
of life is increasingly becoming integrated as part of
clinical trials.16
Does chemotherapy prolong survival?
Advanced stages (IIIB and IV) of lung cancer have a
poor prognosis and a median survival time of only 6
to 8 months.17 Use of the older, toxic alkylating agents
might actually result in shortened survival time.18 A
recent meta-analysis of trials using long-term therapy
of alkylating agents suggested a detrimental effect of
chemotherapy, and obtained a hazard ratio of 1.26
(P=0.095).18 Whether cisplatin-based chemotherapy
prolongs survival significantly in patients with
NSCLC remains debatable.19,20 At least five recent
meta-analyses of a large number of randomised con-
trolled studies have compared chemotherapy and
best supportive care alone in advanced NSCLC.18,21-24
The earlier meta-analyses analysed six to eight studies
and show that cisplatin-based chemotherapy prolongs
survival in patients with advanced NSCLC by approxi-
mately 2 months. The most recent large-scale meta-
analysis used updated data on individual patients from
52 randomised clinical trials involving in 9387 patients,
that took place between 1970 and 1988.18 Of the
advanced disease group, data were available from 11
trials (1190 patients). The absolute survival difference
was calculated by comparing survival rates of patients
in the control arm of cisplatin-based trials with that of
each treatment arm at given points in time. The results
show that compared with the best supportive care, the
patients in the cisplatin-based chemotherapy arm
gained an absolute improvement in survival of 10% at
1 year and an increase in median survival of 1.5 months
(P<0.0001).18
While such survival gains may be considered small
and unimportant to some clinicians, they are of great
Table 1. Symptoms improved by chemotherapy
Symptom Treatment
MVP*8,11 PV + M or I†9 MIP‡10
Cough 66%-71% 45% 70%
Haemoptysis - 91% 92%
Pain 60%-63% 47% 77%
Dyspnoea 59%-65% 78% 46%
Anorexia - 50% 58%
* MVP mitomycin/vinblastine/cisplatin†
 PV + M or I cisplatin/vindesine + mitomycin or ifosfamide‡
 MIP mitomycin/ifosfamide/cisplatin
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importance to the patients.25 The patients must be fully
informed of the facts and be allowed to take part in the
decision of whether or not to use chemotherapy and if
so, which type.
Recommendations on chemotherapy
From the above brief review, it is apparent that cisplatin-
based chemotherapy can result in the palliation of symp-
toms and prolongation of survival time of patients with
advanced NSCLC. The initial performance status is an
important prognostic factor, and patients who have an
initial Karnofsky performance status of 80 to 100 (on a
scale of 1 to 100) have an increased major objective
response rate and survival.26 Cisplatin-based chemo-
therapy may be offered to patients who have a satis-
factory performance status,26 have recently lost less
than 5% of their body weight,27 have evaluable tumour
lesions, or have significant tumour-related symptoms that
would not be readily relieved by medication or radio-
therapy. The response to treatment should be assessed
and therapy should be discontinued early if it proves
ineffective. Patients should fully understand the aims,
side effects, and limitations of chemotherapy and should
be fully motivated about their treatment.
It must be realised, however, that the role of
cisplatin-based chemotherapy in NSCLC has remained
uncertain and controversial.19,20,28 More large-scale pro-
spective studies such as the Big Lung Trial28 are needed
to elucidate the effects of cisplatin-based treatment.
New chemotherapeutic agents
In the past few years, many new cytotoxic agents have
been developed that demonstrate improved response
rates of 14% to 38% (mean, approximately 25%) when
used as single agents in the treatment of NSCLC
(Table 2).29-33 Some of these are analogues of agents
with known mechanisms of action; examples are
gemcitabine (a derivative of cytarabine), vinorelbine
(a synthetic vinca alkaloid), and edatrexate (a deriva-
tive of methotrexate). Some of the new drugs have
new mechanisms of action—for example, the taxanes
promote microtubule assembly and inhibit their
depolymerisation, and topoisomerase I inhibitors
prevent DNA replication (Table 2). Paclitaxel and
gemcitabine are briefly reviewed below.
Paclitaxel
Paclitaxel was first reported to have a beneficial
activity in patients with advanced NSCLC in 1993.34,35
Initial studies used a 24-hour infusion schedule to
reduce the incidence of hypersensitivity reactions.
With the demonstration that the triple premedication
schedule (corticosteroid, antihistamine, H2-receptor
antagonist) was effective in alleviating hypersen-
sitivity reactions, short infusion schedules (1-hour or
3-hour) were used and were found to produce equiva-
lent efficacy and less myelosuppression.30 Currently,
3-hour short infusion schedules are mainly used.
Paclitaxel as a single agent
Single-agent activity of paclitaxel to treat NSCLC
has now been confirmed.30 Despite a variety of doses
(175 mg/m2 to 250 mg/m2) and different schedules
(1-hour, 3-hour, 24-hour, 3-weekly infusions), 10
studies involving 316 patients have demonstrated a
superior mean response rate of 27%, which is similar
to the response to standard drug combinations of
the early 1990s, such as cisplatin and etoposide; or
mitomycin, vindesine, and cisplatin.5-7 The median
survival time was 37 weeks and the 1-year survival
rate was 41%.30 A recent study in which paclitaxel
175 mg/m2 was given as an intravenous infusion
over 3 hours weekly for six consecutive weeks of an
8-week cycle (using standard antihypersensitivity
premedication) showed partial responses in 14 (56%)
of 25 patients.36 The median duration of response
was 6.5 months and the 1-year survival rate was 53%.
The marked activity and accepted toxicity (mainly
neurological) of paclitaxel, if confirmed, would
represent an improved schedule of administration.
Paclitaxel plus cisplatin
There have been at least seven reported studies of
paclitaxel used in combination with cisplatin in the
treatment of advanced NSCLC.30 Response rates
between 31% and 52% (mean, 42%) were observed
in a total of 219 patients; the median survival was
45 weeks and the 1-year survival rate was 39%.30
In contrast, existing cisplatin-based chemotherapy
regimens typically give objective response rates of
less than 40% in cases of advanced NSCLC, the
treatment rarely results in a median survival beyond
25 to 30 weeks or a 1-year survival rate of greater
than 20% to 25%.30 The paclitaxel/cisplatin regimen
Table 2. New drugs for advanced non–small-cell lung cancer29-33
Class Drug Response rate
as single agent (%)
Taxane Paclitaxel 21-38
Docetaxel 23-38
Antimetabolite Gemcitabine 17-28
Vinca alkaloid Vinorelbine 14-36
Topoisomerase
I inhibitor Irinotecan 32-34
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is well tolerated, and neurotoxicity (mainly paraesthe-
sia) is the dose-limiting toxicity.
Paclitaxel plus carboplatin
The rationale of combining paclitaxel with carboplatin
rather than with cisplatin is that carboplatin is both
more convenient (no hydration needed) and less
toxic than cisplatin.37 Langer et al38 have reported the
use of paclitaxel at an initial dosage of 135 mg·m-2·d-1
by 24-hour infusion, a sequential dose increase by
40 mg/m2 per cycle to a maximum of 215 mg/m2, and
the co-administration of carboplatin on day 2 at a
targeted area under the concentration-time curve
(AUC) of 7.5 using the Calvert formula.38 Treatment
was repeated at 3-week intervals for six cycles and
subcutaneous granulocyte colony-stimulating factor
was given during the second and subsequent cycles.
The objective response rate to this regimen was 62%
(33/53); five (9%) were complete responses. The
median survival was 53 weeks and the 1-year survival
rate was 54%.38 These results are compared with
existing cisplatin-based chemotherapy regimens in
Table 3.
The paclitaxel/carboplatin regimen has sub-
sequently been modified in schedules by other groups.
Greco and Hainsworth39 administered paclitaxel 225
mg/m2 by 1-hour infusion, followed immediately by
carboplatin at an AUC of 6.0, using a repeating
21-day cycle; 38 (40%) of 94 patients had objective
responses (3 complete and 35 partial responses) and
the median survival and 1-year survival rate were 8
months and 42%, respectively. DeVore et al40 obtained
an overall response rate to paclitaxel/carboplatin
infusion of only 25%; they noted different toxicity
profiles and greater myelosuppression after 24 hours
of paclitaxel treatment as well as more neurotoxicity
and arthralgia/myalgia due to the 1-hour infusion.
Langer et al41 have studied the following modified
schedules: (1) paclitaxel 175 mg/m2 given in 1 hour
with an intrapatient dose escalation of 35 mg/m2 per
cycle to a maximum of 280 mg/m2, plus carboplatin
at an AUC of 7.5 every 3 weeks; and (2) paclitaxel
135 mg/m2 with an intrapatient dose escalation of
40 mg/m2 per cycle, to a maximum dose of 215 mg/m2,
plus the same carboplatin dosage as in regimen (1).
For the cohort using regimen (1), the objective response
rate was 55%, but the incidence of neurotoxicity was
intolerable and dose-limiting when the paclitaxel dose
exceeded 215 mg/m2. In contrast, for the cohort using
regimen (2), which used lower doses of paclitaxel,
treatment was more tolerable but gave a lower response
rate of 26%.41 The optimal dose schedule remains to
be defined.42
Gemcitabine
Gemcitabine is a pyrimidine nucleoside analogue
that is related to cytarabine; gemcitabine acts as an
antimetabolite.
Gemcitabine as a single agent
The single-agent activity of gemcitabine in advanced
NSCLC has now been confirmed.32,43,44 Using a
dosage of 1000 to 1250 mg/m2, administered as a
30-minute infusion once weekly for 3 weeks followed
by a week of rest, four studies involving 398 evaluable
patients have demonstrated a mean response rate of
21% and a median survival of 34 weeks. Comparative
studies have shown that single-agent gemcitabine is,
like paclitaxel, at least as effective as the combination
of cisplatin/etoposide in the treatment of advanced
NSCLC and has a better toxicity profile.45,46
Table 3. Comparison of existing cisplatin- and paclitaxel-based chemotherapy
Treatment Response rate (%)  Median survival 1-year survival rate
 Complete Partial time (weeks) (%)
Current cisplatin-based chemotherapy - ≤40 25-30 20-25
Paclitaxel as single agent30 - 27 37 41
Paclitaxel/cisplatin regimen30 - 42 45 39
Paclitaxel/carboplatin38 9 53 53 54
Table 4. Phase II clinical trials of gemcitabine and cisplatin combination therapy
Study No. of No. of No. of Response Median survival
evaluable patients CRs* PRs† rates (%) time (months)
Natale,44 1997 52 1 21 42 9.8
Abratt et al,47 1997 50 2 24 52 13.0
Crino et al,48 1997 48 1 25 54 14.4
Einhorn,49 1997 27 0 10 37 8.4
* CRs complete response
† PRs partial response
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Gemcitabine plus cisplatin or carboplatin
At least four phase II trials of gemcitabine/cisplatin
in advanced NSCLC have been reported (Table 4).44,47-49
The overall response rate of 177 evaluable patients
was 47.5% (range 37.0%-54.0%); there were four
complete responders. The 1-year survival rate was
61% in a South African study.47 Dose-limiting toxicities
were primarily haematological. Grade 3/4 granulo-
cytopenia and thrombrocytopenia were observed in up
to 58% and 52% of treated patients, respectively.
Febrile neutropenia was rare and there were no
episodes of serious bleeding. Nausea and vomiting
were common, as was expected with a cisplatin-
containing regimen. Other toxicities, such as elevation
of liver transaminase levels, rashes, and lethargy,
were generally mild and reversible. These results
appear to be encouraging, and further phase II/III
studies are warranted. Studies of the gemcitabine/
carboplatin regimen are underway,50 and results are
awaited with interest.
Symptomatic benefit and elderly patients
Thatcher et al51 have examined the effect of gem-
citabine therapy on patients’ symptomatic relief and
change in performance status. The results showed that
symptom improvement occurs in a significant propor-
tion of patients with moderate to severe symptoms
(73% for cough, 100% for haemoptysis, 37% for
pain, 51% for dyspnoea, and 38% for anorexia). In
addition, 52% of patients had improvement in their
performance status, and in about one third of patients
treated with gemcitabine, palliative radiotherapy was
no longer required.51
Gemcitabine has a mild toxicity profile and has thus
been administered to elderly patients older than 65
years.52 Gemcitabine’s activity and tolerability in the
elderly group is similar to those in the younger age
group (aged <65 years); the study concluded that
gemcitabine should be considered as an alternative
for the treatment of elderly patients with advanced
NSCLC.
Pulmonary toxicity of gemcitabine
The safety profile of gemcitabine is good. Myelo-
toxicity is the major dose-limiting toxicity, but very
few patients (<1%) have required discontinuation of
therapy.29,32,43,44,53 Other side effects include mild to
moderate nausea and vomiting, influenza-like symp-
toms, mild skin rash, reversible elevation of serum
transaminases levels, fever, and dyspnoea; therapy is
seldom discontinued, however.53-55 A recent report
has drawn attention to a life-threatening pulmonary
toxicity in three patients who developed tachycardia,
marked hypoxaemia, and interstitial infiltration, symp-
toms which are consistent with non-cardiac pulmonary
oedema.56 Two of the patients died and post-mortem
examination confirmed acute respiratory distress
syndrome, which was consistent with drug-induced
pulmonary toxicity.56 Withdrawing gemcitabine early
and starting a course of corticosteroids and diuretics
are recommended for averting a fatal outcome. This
special pulmonary toxicity is similar to that observed
during cytarabine therapy.57-59
Gemcitabine/paclitaxel as salvage therapy
The subsequent treatment of patients with NSCLC
whose condition has relapsed or for whom initial
cisplatin-based chemotherapy was unsuccessful is
difficult. A phase II study of paclitaxel/gemcitabine
combination therapy has been conducted among patients
with NSCLC who had failed first-line cisplatin-based
chemotherapy or docetaxel therapy.60 Of the 26 patients
evaluated, two (8%) gave complete responses and five
(21%) gave partial responses; the median duration of
response was 2.5 months and the median survival was
8 months.60 The regimen is therefore well tolerated.
This preliminary result is encouraging and further
studies are warranted.
Conclusion
Paclitaxel, gemcitabine, and other drugs such as
docetaxel and vinorelbine are promising new chemo-
therapeutic agents in the treatment of advanced
NSCLC. Their use seems to achieve the two aims of
therapy—namely, to palliate disease symptoms and to
improve the median survival rate. There are currently
no data to show a survival benefit from using these
new drugs over cisplatin-based chemotherapy, but
comparative studies are underway.30,44,61,62 Although
the toxicities of these two new drugs are tolerable, the
optimal dose and treatment schedules are yet to be
defined. Efforts to identify new active agents and to
determine optimal combinations and dose schedules
of existing regimens must continue.
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